COMMUNIQUÉS West-GlobeNewswire

TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology

21/02/2018 - 13:30

Umbralisib is structurally distinct from other PI3K delta inhibitors with greater selectivity to PI3K delta and unique complementary inhibition of casein kinase-1 (CK1) epsilon Single agent umbralisib was well tolerated [...]

Recro Pharma to Host Analyst and Investor Day on February 28, 2018

21/02/2018 - 13:00

MALVERN, Pa., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH ), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today [...]

Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors

21/02/2018 - 13:00

HOUSTON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]

Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call

21/02/2018 - 13:00

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth [...]

FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018

21/02/2018 - 13:00

SAN FRANCISCO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN ), a science-based biopharmaceutical company, today announced that it will report fourth quarter and full year 2017 financial results on [...]

Update: Natus to Present at Raymond James 39th Annual Institutional Investors Conference

21/02/2018 - 13:00

PLEASANTON, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: BABY ) today announced that Jonathan Kennedy, Executive Vice-President and Chief Financial Officer will present at the Raymond [...]

Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

21/02/2018 - 13:00

BERKELEY HEIGHTS, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC ) (NASDAQ: CYCCP ) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target [...]

Purepoint Uranium Acquires Strategic Land Positions in the Athabasca Basin, Saskatchewan

21/02/2018 - 12:45

TORONTO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (the “ Company ” or “ Purepoint ”) (TSX.V:PTU) today reported that since October, 2017 it has acquired through staking an additional 52,479 [...]

Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH

21/02/2018 - 12:00

LIVONIA, Mich., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP ), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders [...]

CURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to Uplisting

21/02/2018 - 12:00

OXNARD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced Gene Salkind, M.D. joined the company’s Advisory Board and also [...]

New medicine for house dust mite allergic rhinitis and allergic asthma now available in France

21/02/2018 - 10:00

Copenhagen, 2018-02-21 10:00 CET (GLOBE NEWSWIRE) -- Allergy immunotherapy company ALK today announced that its sublingual allergy immunotherapy (SLIT) tablet ACARIZAX ® is now available on prescription in France for [...]

Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia

21/02/2018 - 09:49

Press release - No. 5/2018 Zealand Pharma reports completion of the first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia Last patient visit concluded in the multinational Phase 3 trial, with [...]

Veritas Pharma Provides Corporate Update on Q1 2018

21/02/2018 - 09:10

VANCOUVER, British Columbia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) , (“Veritas” or the “Company”) is pleased to provide an official corporate update on its [...]

Saniona AB: Saniona publishes its year-end report for 2017

21/02/2018 - 08:01

PRESS RELEASE February 21, 2018 Financial highlights Jan - Dec 2017 (Jan - Dec 2016) · Net revenues were SEK 20.7 M (74.9 M) · EBIT was SEK -57.2 M (4.2 M) · Net profit/loss was SEK -49.2 M (2.2 M) · Earnings per share [...]

Motif Bio to Present Iclaprim Data at ECCMID 2018

21/02/2018 - 08:00

Phase 3 trial results for REVIVE-2 in patients with ABSSSI Potential cost savings opportunities with iclaprim versus vancomycin Iclaprim in vitro susceptibility data NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Motif Bio [...]

NeuroSearch – Updated financial calendar for 2018

21/02/2018 - 08:00

Announcement no. 2-18 Page 1 of 1 Announcement 21 February 2018 NeuroSearch A/S (NEUR) hereby announces an update on the company’s financial calendar for 2018. 30 April 2018 Annual General Meeting 30 August 2018 Interim [...]

Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors

21/02/2018 - 07:16

Basel, Switzerland, February 21, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Chief Executive Officer Ronald Scott will retire after 18 years with the company. Basilea's Board of Directors has [...]

ProPhase Labs, Inc. Announces New Compensatory Arrangement With Chief Executive Officer and Termination of Stockholder Rights Plan

21/02/2018 - 01:15

DOYLESTOWN, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH ) ( www.ProPhaseLabs.com ), a vertically integrated and diversified branding, marketing and technology company with deep experience in [...]

National Research Corporation Declares Quarterly Dividend

21/02/2018 - 00:00

Lincoln, Nebraska, Feb. 20, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRCIA and NRCIB) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 (ten cents) per [...]